Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model


Christelle Remy-Ziller, et al.
Human Vaccines & Immunotherapeutics, 2017, 19:0 – Download the article
Publication